Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
Provided By GlobeNewswire
Last update: Sep 9, 2025
Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors
Achievement of milestone extends anticipated cash runway into first quarter of 2027
NASDAQ:XLO (12/10/2025, 3:13:14 PM)
0.7256
0 (-0.6%)
Find more stocks in the Stock Screener
